Stocks Health care XBIT
NASDAQ · Health careXBiotech Inc. (XBIT)
It posted a net loss of $45.1M. In fiscal 2025 capital spending exceeded operating cash flow by $40.2M. At June 30, 2026 it held $109.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What XBiotech Inc. does
XBiotech Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XBIT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$45.5M | -$1.49 | -$40.2M |
| 2024 | n/a | -$38.5M | -$1.26 | -$32.3M |
| 2023 | $0 | -$24.6M | -$0.81 | -$19.1M |
| 2022 | $4M | -$32.9M | -$1.08 | -$15.4M |
| 2021 | $18.4M | -$17.4M | -$0.58 | $65.9M |
| 2020 | $44M | -$11.2M | -$0.36 | -$68.9M |
Latest SEC filings
What XBiotech Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026
- April 29, 2026Annual report (amended) 10-K/A · period to December 31, 2025
- March 13, 2026Annual report 10-K · period to December 31, 2025
- March 11, 2026
- January 23, 2026Passive stake changed SCHEDULE 13G/A
- January 23, 2026Passive stake changed SCHEDULE 13G/A
- December 9, 2025
- November 12, 2025Quarterly report 10-Q · period to September 30, 2025
- October 15, 2025
Questions about XBIT
What does XBiotech Inc. do?
XBiotech Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XBIT.
Is XBiotech Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $45.1M.
When did XBiotech Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.
Similar companies
Follow XBIT
Get an email when XBiotech Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow XBIT: get an email when it filesWhere the numbers come from
Financial figures are the values XBiotech Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.